A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation–associated TMA

伊库利珠单抗 医学 血栓性微血管病 内科学 临床终点 造血干细胞移植 肾功能 移植 前瞻性队列研究 胃肠病学 累积发病率 外科 免疫学 补体系统 临床试验 免疫系统 疾病
作者
Sonata Jodele,Christopher E. Dandoy,Paibel Aguayo‐Hiraldo,Adam Lane,Ashley Teusink‐Cross,Anthony Sabulski,Kana Mizuno,Benjamin L. Laskin,Jason L. Freedman,Stella M. Davies
出处
期刊:Blood [Elsevier BV]
卷期号:143 (12): 1112-1123 被引量:11
标识
DOI:10.1182/blood.2023022526
摘要

Abstract High-risk, complement mediated, untreated transplant-associated thrombotic microangiopathy (hrTMA) has dismal outcomes due to multi-organ dysfunction syndrome (MODS). The complement C5 blocker eculizumab shows promising results in hrTMA, but has not been prospectively studied in hematopoietic stem cell transplant (HCT) recipients. We performed the first multi-institutional prospective study in children and young adults to evaluate eculizumab as an early targeted intervention for hrTMA/MODS. We hypothesized that eculizumab would more than double survival in HCT recipients with hrTMA, compared to our prior study of prospectively screened, untreated hrTMAs serving as historical controls. HrTMA features (elevated terminal complement (sC5b-9) and proteinuria measured by random urine protein/creatinine ratio (≥1mg/mg)) were required for inclusion. The primary endpoint was survival at 6 six-months from hrTMA diagnosis. Secondary endpoints were cumulative incidence of MODS 6 months after hrTMA diagnosis and 1-year posttransplant survival. Eculizumab dosing included intensive loading, induction, and maintenance phases for up to 24 weeks of therapy. All 21 evaluated study subjects had MODS. Primary and secondary study endpoints were met by demonstrating survival of 71% (P < .0001) 6 months after hrTMA diagnosis and 62% 1 year after transplant. Of fifteen survivors, 11 (73%) fully recovered organ function and are well. Our study demonstrates significant improvement in survival and recovery of organ function in hrTMA using an intensified eculizumab dosing and real time biomarker monitoring. This study serves as a benchmark for planning future studies that should focus on preventative measures or targeted therapy to be initiated prior to organ injury. This trial was registered at www.clinicaltrials.gov as #NCT03518203.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
谦让成协完成签到,获得积分10
5秒前
7秒前
王半书完成签到 ,获得积分10
8秒前
11秒前
guantlv发布了新的文献求助10
13秒前
朱婷完成签到 ,获得积分10
13秒前
俏皮的采波完成签到,获得积分10
15秒前
杨永佳666完成签到 ,获得积分10
17秒前
自觉石头完成签到 ,获得积分10
18秒前
Wangruojin_完成签到,获得积分20
18秒前
UUU完成签到 ,获得积分10
20秒前
Wangruojin_发布了新的文献求助10
21秒前
lige完成签到 ,获得积分10
22秒前
guantlv完成签到,获得积分10
22秒前
满意代萱完成签到 ,获得积分10
24秒前
zlx完成签到 ,获得积分10
26秒前
追寻的续完成签到 ,获得积分10
26秒前
量子星尘发布了新的文献求助10
28秒前
芝诺的乌龟完成签到 ,获得积分0
32秒前
JJ完成签到 ,获得积分10
36秒前
mrwang完成签到 ,获得积分10
36秒前
逢场作戱__完成签到 ,获得积分10
39秒前
上善若水呦完成签到 ,获得积分10
44秒前
Wilson完成签到 ,获得积分10
44秒前
45秒前
神外王001完成签到 ,获得积分10
47秒前
H1lb2rt完成签到 ,获得积分10
51秒前
大模型应助方俊驰采纳,获得10
55秒前
Zeeki完成签到 ,获得积分10
55秒前
Dong完成签到 ,获得积分10
57秒前
59秒前
龙王爱吃糖完成签到 ,获得积分10
59秒前
张三完成签到 ,获得积分10
1分钟前
风衣拖地完成签到 ,获得积分10
1分钟前
方俊驰发布了新的文献求助10
1分钟前
研友_Z1eDgZ完成签到,获得积分10
1分钟前
Libgenxxxx完成签到,获得积分10
1分钟前
江幻天完成签到,获得积分10
1分钟前
Lrcx完成签到 ,获得积分10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
A new approach to the extrapolation of accelerated life test data 1000
Coking simulation aids on-stream time 450
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
Novel Preparation of Chitin Nanocrystals by H2SO4 and H3PO4 Hydrolysis Followed by High-Pressure Water Jet Treatments 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4015568
求助须知:如何正确求助?哪些是违规求助? 3555555
关于积分的说明 11318118
捐赠科研通 3288718
什么是DOI,文献DOI怎么找? 1812284
邀请新用户注册赠送积分活动 887882
科研通“疑难数据库(出版商)”最低求助积分说明 812015